Riskpilot← Back to searchSign inGet full accessVIROSAFE NORGE AS
ASActiveOrg 9827987603 Etg Torggata 3, 2317 HamarOther software publishing · NACE 5829Est. 20016 employeeswww.virosafe.no
Revenue 2025
NOK 13,5M
-10% vs 2024
EBITDA margin
7.2%
+1229% vs 2024
Equity ratio
10.0%
Financial strength
Net profit 2025
NOK 728K
+799% vs 2024
| Revenue | NOK 13,5M | -10% |
| EBITDA | NOK 970K | +1229% |
| Net profit | NOK 728K | +799% |
| Total assets | NOK 4,1M | +6% |
| Equity | NOK 413K | +124% |
| Employees | 6 | — |
Legal name
VIROSAFE NORGE AS
Org number
982798760
Legal form
Aksjeselskap
NACE code
5829 · Other software publishing
Founded
5. januar 2001
Share capital
NOK 302 200
Employees
6 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap eller styrets leder alene.
Company purpose
Salg av produkter og tjenester innen datasikkerhet/datanettverk samt dertil hørende virksomhet, herunder deltakelse i andre selskaper.
Address
3 Etg Torggata 3, 2317 Hamar
Website
www.virosafe.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 13 250 | 13 223 | 14 956 | 15 118 | 13 544 |
| Staff expenses | −5 145 | −5 246 | −5 878 | −6 011 | −3 852 |
| EBITDA | −86 | −115 | −178 | −86 | 970 |
| Depreciation & amort. | −0 | −0 | −11 | −11 | −11 |
| EBIT | −86 | −115 | −189 | −97 | 959 |
| Net financials | 112 | 17 | −115 | −33 | −19 |
| Profit before tax | 26 | −98 | −304 | −130 | 940 |
| Tax | 8 | −22 | −66 | −26 | 212 |
| Net profit | 19 | −77 | −238 | −104 | 728 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 922 | 3 463 | 3 188 | 3 893 | 4 112 |
| Equity | 603 | 527 | 289 | 185 | 413 |
| Long-term debt | 0 | 0 | 0 | 0 | 4 |
| Short-term debt | 2 319 | 2 936 | 2 899 | 3 708 | 3 696 |
| Total debt | 2 319 | 2 936 | 2 899 | 3 708 | 3 700 |
EBITDA margin
7.2%
This company
15.8%
Market median
-54% vs market
20212025
Equity ratio
10.0%
This company
38.2%
Market median
-74% vs market
20212025
Return on equity
176.4%
This company
18.4%
Market median
+859% vs market
20212025
Net profit margin
5.4%
This company
8.1%
Market median
-33% vs market
20212025
Asset turnover
3.29×
This company
1.12×
Market median
+194% vs market
20212025
Debt / equity
8.97×
This company
0.62×
Market median
-1347% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PA Chief Executive Officer | Chief Executive Officer | 2013 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2013 | |
| Chairman | 2013 | |
| Board of Directors | 2013 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 42.06% | 42.06% | 2022 | |
| Company | 26.11% | 26.11% | 2022 | |
| Company | 15.35% | 15.35% | 2022 | |
| Company | 15.35% | 15.35% | 2022 | |
| Company | 1.13% | 1.13% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Hubro Consult As
VIROSAFE NORGE AS Board members of VIROSAFE NORGE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Pål Arne Martinsen | Chief Executive Officer | 0 companies |
| Widar Stuvland | Board of Directors | 0 companies |
| Erling André Vold | Chairman | 0 companies |
| Tore Løvås | Board of Directors | 0 companies |